Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 683

1.
2.

Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.

Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL.

Am J Cardiol. 1999 Aug 1;84(3):289-93.

PMID:
10496437
3.
4.

Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.

Association of Black Cardiologists (ABC) Candesartan Study Group.

Heart Dis. 2000 Nov-Dec;2(6):392-9.

PMID:
11728289
5.

Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.

Ogihara T, Arakawa K.

J Hum Hypertens. 1999 Jan;13 Suppl 1:S27-31; discussion S33-4. Review.

PMID:
10076918
6.
8.

Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group.

Tanser PH, Campbell LM, Carranza J, Karrash J, Toutouzas P, Watts R.

Am J Hypertens. 2000 Feb;13(2):214-8.

PMID:
10701823
10.

A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.

Palma-Gamiz JL, Pêgo M, Marquez E, Pujol M, Olivan J, Alegría E, Sagastagoitia-Gorostiza JD, Gonzalez-Juanatey JR.

Clin Drug Investig. 2007;27(6):407-17.

PMID:
17506591
12.

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T; Effect Study Group.

Blood Press. 2001;10(1):43-51.

PMID:
11332334
14.
15.

[Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].

Baumgart P, Reismann J, Pohlmeyer H, Düsing R.

Dtsch Med Wochenschr. 2001 May 11;126(19):547-50. German.

PMID:
11402910
17.

Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.

Sever PS.

J Hypertens Suppl. 1997 Dec;15(6):S9-12. Review.

PMID:
9493121
18.

Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.

Fogari R, Mugellini A, Derosa G; CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group.

J Renin Angiotensin Aldosterone Syst. 2007 Sep;8(3):139-44. Erratum in: J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):168. Derosa, Giuseppe [added]; CANDIA (CANdesartan and DIuretic vs. Amlodipine in hypertensive patients) Study Group [added].

PMID:
17907102
19.

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.

Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, Watanabe LA, Barragan J, Matadamas N, Mendiola A, Woo KS, Zhu JR, Mejia AD, Bunt T, Dumortier T, Smith RD.

Clin Ther. 2000 Oct;22(10):1186-203.

PMID:
11110230
20.

Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.

Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E; CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.

J Hypertens. 2005 Feb;23(2):435-44.

PMID:
15662233

Supplemental Content

Support Center